ING Group’s Halozyme HALO Stock Holding History

ING Group’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-90,700	Closed	-$6.65M	–	589
2025 Q3	$6.65M	Buy	+90,700	New	+$6.02M	0.04%	237

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ING Group's HALO Position: Q4 2025 in Review

ING Group sold out of Halozyme (HALO) in Q4 2025, closing a stake of 90,700 shares — an estimated $6.65M sold.

ING Group first reported a position in HALO in Q3 2025 and held it in 1 quarter. The position peaked at $6.65M in Q3 2025. 618 funds tracked by Wall St. Rank hold HALO as of Q4 2025.

ING Group reported no remaining Halozyme position as of Q4 2025 after selling out during the quarter.
ING Group sold 90,700 Halozyme shares in Q4 2025, an estimated $6.65M.
ING Group first reported a position in Halozyme in Q3 2025 and held it in 1 quarter.
ING Group's Halozyme position peaked at $6.65M in Q3 2025.
618 funds tracked by Wall St. Rank held Halozyme as of Q4 2025.

Based on ING Group's 13F filing for Q4 2025, filed 11 Feb 2026.